[go: up one dir, main page]

MX2019014187A - Oligonucleotidos antisentido para modular la expresion de requisito de alta temperatura a1 (htra1). - Google Patents

Oligonucleotidos antisentido para modular la expresion de requisito de alta temperatura a1 (htra1).

Info

Publication number
MX2019014187A
MX2019014187A MX2019014187A MX2019014187A MX2019014187A MX 2019014187 A MX2019014187 A MX 2019014187A MX 2019014187 A MX2019014187 A MX 2019014187A MX 2019014187 A MX2019014187 A MX 2019014187A MX 2019014187 A MX2019014187 A MX 2019014187A
Authority
MX
Mexico
Prior art keywords
antisense oligonucleotides
expression
htra1 expression
modulating
modulating htra1
Prior art date
Application number
MX2019014187A
Other languages
English (en)
Inventor
Iacone Roberto
Ottosen Søren
Hagedorn Peter
PEDERSEN Lykke
Kammler Susanne
Traustason Sindri
Alvarez Sánchez Rubén
Rye Hudlebusch Heidi
Berrera Marco
Dieckmann Andreas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019014187A publication Critical patent/MX2019014187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21108—HtrA2 peptidase (3.4.21.108)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a oligonucleótidos (oligómeros) antisentido que son complementarios a HTRA1, que conducen a la modulación de la expresión de HTRA1. La modulación de la expresión de HTRA1 resulta beneficiosa para un abanico de trastornos médicos, tales como la degeneración macular, por ejemplo, la degeneración macular asociada a la edad.
MX2019014187A 2017-06-01 2018-05-30 Oligonucleotidos antisentido para modular la expresion de requisito de alta temperatura a1 (htra1). MX2019014187A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17173964 2017-06-01
EP17209535 2017-12-21
EP17209407 2017-12-21
PCT/EP2018/064221 WO2018220034A1 (en) 2017-06-01 2018-05-30 Antisense oligonucleotides for modulating htra1 expression

Publications (1)

Publication Number Publication Date
MX2019014187A true MX2019014187A (es) 2020-01-27

Family

ID=62245334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014187A MX2019014187A (es) 2017-06-01 2018-05-30 Oligonucleotidos antisentido para modular la expresion de requisito de alta temperatura a1 (htra1).

Country Status (19)

Country Link
US (3) US20190055564A1 (es)
EP (1) EP3630976A1 (es)
JP (1) JP7169995B2 (es)
KR (1) KR20200015608A (es)
CN (1) CN110691849A (es)
AU (1) AU2018277219A1 (es)
BR (1) BR112019025290A2 (es)
CA (1) CA3062590A1 (es)
CL (1) CL2019003337A1 (es)
CO (1) CO2019013317A2 (es)
CR (1) CR20190543A (es)
IL (1) IL271039A (es)
MA (1) MA49278A (es)
MX (1) MX2019014187A (es)
PE (1) PE20191845A1 (es)
PH (1) PH12019502636A1 (es)
RU (1) RU2019143004A (es)
TW (1) TW201907008A (es)
WO (1) WO2018220034A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45620A (fr) 2016-07-01 2019-05-08 Hoffmann La Roche Oligonucléotides antisens pour la modulation de l'expression de htra1
CA3090901A1 (en) 2018-02-12 2019-08-15 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
EP4202061A4 (en) * 2020-08-20 2024-09-11 Genome Opinion Inc. Biomarker for diagnosing age-related macular degeneration, and use thereof
US20240254213A1 (en) * 2020-10-30 2024-08-01 Hideaki Hara Gdf15 modulator for use in inhibition of ocular tissue fibrosis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
NZ503765A (en) 1997-09-12 2002-04-26 Exiqon As Bi-cyclic and tri-cyclic nucleotide analogues
AU5290499A (en) * 1998-08-03 2000-02-28 Novartis Ag Human htra serine protease
EP1152009B2 (en) 1999-02-12 2017-09-06 Daiichi Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
JP2002543214A (ja) 1999-05-04 2002-12-17 エクシコン エ／エス Ｌ−リボ−ｌｎａ類縁体
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU2003281969B2 (en) 2002-11-18 2011-01-27 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
WO2006127913A2 (en) * 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Modulation of lmw-ptpase expression
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
CN102908630B (zh) 2006-01-27 2014-11-19 Isis制药公司 6-修饰的双环核酸类似物
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US7547684B2 (en) 2006-05-11 2009-06-16 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
WO2008013893A2 (en) 2006-07-26 2008-01-31 Yale University Diagnosis and treatment of age related macular degeneration
WO2008067040A2 (en) * 2006-10-06 2008-06-05 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
TW200911290A (en) 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
ATE538127T1 (de) 2007-07-05 2012-01-15 Isis Pharmaceuticals Inc 6-disubstituierte bicyclische nukleinsäureanaloga
WO2009059318A2 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Genes and polymorphisms associated with amd
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
FR2965278B1 (fr) 2010-09-23 2014-10-10 Univ Caen Basse Normandie Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations
US9751909B2 (en) 2011-09-07 2017-09-05 Marina Biotech, Inc. Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
EP2850184A4 (en) * 2012-05-16 2016-01-27 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION
CN117126846A (zh) 2012-11-15 2023-11-28 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合物
WO2018087200A1 (en) * 2016-11-11 2018-05-17 Roche Innovation Center Copenhagen A/S Therapeutic oligonucleotides capture and detection

Also Published As

Publication number Publication date
KR20200015608A (ko) 2020-02-12
US20200157546A1 (en) 2020-05-21
CL2019003337A1 (es) 2020-05-15
CA3062590A1 (en) 2018-12-06
TW201907008A (zh) 2019-02-16
RU2019143004A (ru) 2021-07-09
AU2018277219A1 (en) 2019-12-19
IL271039A (en) 2020-01-30
US20220042022A1 (en) 2022-02-10
PH12019502636A1 (en) 2020-06-08
BR112019025290A2 (pt) 2020-06-23
PE20191845A1 (es) 2019-12-31
CR20190543A (es) 2020-02-10
US20190055564A1 (en) 2019-02-21
JP7169995B2 (ja) 2022-11-11
JP2020521491A (ja) 2020-07-27
CO2019013317A2 (es) 2020-01-17
EP3630976A1 (en) 2020-04-08
MA49278A (fr) 2020-04-08
CN110691849A (zh) 2020-01-14
WO2018220034A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
PH12018502707A1 (en) Antisense oligonucleotides for modulating htra1 expression
PH12020500252A1 (en) Compounds as modulators of ror gamma
PH12019502636A1 (en) Antisense oligonucleotides for modulating htra1 expression
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12017500653A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
MY201080A (en) Nlrp3 modulators
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
PH12016501613A1 (en) Pyrazines modulators of gpr6
MX367852B (es) Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii.
EA201891258A1 (ru) Новые производные диаминопиридина
AR112908A1 (es) Oligonucleótidos antisentido para modular la expresión de htra1
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
MX2017008162A (es) Sintesis total de trioxacarcina dc-45-a2 y preparacion de analogos de trioxacarcina.